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Abstract
Amyotrophic lateral sclerosis (ALS) is characterised by progressive motor neuron degeneration. Although there are
over 40 genes associated with causal monogenetic mutations, the majority of ALS patients are not genetically
determined. Causal ALS mutations are being increasingly mechanistically studied, though how these mechanisms
converge and diverge between the multiple known familial causes of ALS (fALS) and sporadic forms of ALS
(sALS) and furthermore between different neuron types, is poorly understood. One common pathway that is
implicated in selective motor neuron death is enhanced -amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
(AMPAR)-mediated excitoxicity. Specifically, human in vitro and pathological evidence has linked the C9orf72
repeat expansion mutation to a relative increase in the Ca2+-permeable AMPAR population due to AMPAR subunit
dysregulation. Here, we provide the first comparative quantitative assessment of the expression profile of AMPAR
subunit transcripts, using BaseScope, in post-mortem lower motor neurons (spinal cord, anterior horn), upper
motor neurons (motor cortex) and neurons of the pre-frontal cortex in sALS and fALS due to mutations in SOD1
and C9orf72. Our data indicated that AMPAR dysregulation is prominent in lower motor neurons in all ALS cases.
However, sALS and mutant C9orf72 cases exhibited GluA1 upregulation whereas mutant SOD1 cases displayed
GluA2 down regulation. We also showed that sALS cases exhibited widespread AMPAR dysregulation in the motor
and pre-frontal cortex, though the exact identity of the AMPAR subunit being dysregulated was dependent on brain
region. In contrast, AMPAR dysregulation in mutant SOD1 and C9orf72 cases was restricted to lower motor neurons
only. Our data highlight the complex dysregulation of AMPAR subunit expression that reflects both converging
and diverging mechanisms at play between different brain regions and between ALS cohorts.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly pro-
gressive and invariably fatal neurodegenerative disease
characterised by degeneration of motor neurons of the
brain and spinal cord. The last 10 years has seen con-
siderable progress in the genetic understanding of ALS
with over 40 associated genes known to harbour genetic
mutations associated with the disease. However, only a
small proportion of total ALS cases (5–10%) are linked
to hereditary mutations and the proportion of appar-
ently sporadic ALS (sALS) cases having a genetic basis
remains∼10% [1,2]. In this regard, modelling sALS has
been challenging and the majority of ALS research has
been conducted on models based on genetic mutations
including the C9orf72 repeat expansion (C9orf72RE)
mutation and mutations to SOD1, which represent the
two most frequent known familial and sporadic ALS
mutations [1,2]. Whilst many mutations share general
pathological features with sALS, including TDP-43
pathology [3], there is an appreciation that the diversity
of mutated genes are also likely to reflect diverse path-
ways and mechanisms that underlie the degeneration
of motor neurons in ALS [4,5]. The extrapolation and
relevance of how these pathways converge and diverge
between the multiple known familial causes of ALS and
sporadic forms of ALS is largely unknown.
Glutamate-mediated excitotoxicity has been a
major hypothesis in ALS motor neuron degenera-
tion for ∼25 years, with α-amino-3-hydroxyl-5-methyl-
4-isoxazole-propionate receptors (AMPARs) emerging
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as a likely candidate for glutamate receptor-mediated
excitotoxicity [6]. Crucially, glutamate-gated
AMPAR ion channels are composed of four poten-
tial subunits, GluA1–4, each of which genetically
encode Ca2+-permeable subunits [7]. The GluA2
subunit is however almost uniformly subject to
post-transcriptional RNA editing such that inser-
tion of edited GluA2 subunits into the AMPAR
complex confers Ca2+-impermeability to the ion
channel. Dysregulation of AMPAR subunits to gener-
ate increased Ca2+-permeable AMPAR populations is
thought to contribute to excitotoxicity in ALS motor
neurons [8–15]. Indeed, recently we showed that
C9orf72RE patient motor neurons displayed a vul-
nerability to AMPAR-mediated excitotoxicity due to
a C9orf72RE-dependent increase in Ca2+-permeable
AMPAR expression through an abnormal increase
in GluA1 subunit expression [15]. However, altered
AMPAR properties were not observed in human cor-
tical neurons suggesting that the C9orf72RE mutation
imparts a selective AMPAR-associated mechanism of
excitotoxicity onto motor neurons [15]. The degree to
which mechanisms are conserved across specific brain
areas and furthermore other ALS patients with different
familial and sporadic aetiologies remains to be clarified.
Noting sporadic and C9orf72RE ALS patients, but
not SOD1 mutation patients, typically exhibit shared
TDP-43 pathology [16] we have therefore, for the first
time, compared the regional expression of AMPARs
in sALS patients together with patients with SOD1
(I114T) and C9orf72RE mutations. To accomplish
this we used a high-resolution in situ hybridisation
technique, BaseScope, to systematically characterise
the expression of AMPAR subunit transcripts at the
single-cell level in post-mortem spinal cord (anterior
horn), prefrontal cortex and motor cortex from the dif-
ferent ALS cohorts with respect to age- and sex-matched
controls with no clinical or pathological evidence of
neurological disease. Furthermore, we have used human
pluripotent stem cell technology to examine the degree
of GluA2 RNA editing within sALS patient-derived
neurons. Our data implicate notable regional AMPAR
subunit dysregulation across all brain regions examined
in sALS patients and a restriction of AMPAR subunit
dysregulation to the spinal cord in SOD1 (I114T) and
C9orf72RE patients.
Materials and methods
Case identification and ethics
ALS post-mortem samples were obtained from theMed-
ical Research Council (MRC) Edinburgh Brain Bank
and had separately undergone whole genome sequenc-
ing for genetic identification [2]. Our study used three
separate cases for each of C9orf72 repeat expansion,
sporadic and SOD1 ALS cases. Age and sex-matched
control cases with respect to the ALS cases, exhibited
no evidence of neurodegenerative disease pathology and
were obtained from the Edinburgh Sudden Death Brain
Bank. All clinical data were collected as part of the Scot-
tish Motor Neurone Disease Register and Care Audit
Research and Evaluation for Motor Neurone Disease
platform (Ethics approval from Scotland A Research
Ethics Committee 10/MRE00/78 and 15/SS/0216) and
all patients consented to the use of their data during life.
All post-mortem tissue was collected via the Edinburgh
Brain Bank (Ethics approval from East of Scotland
Research Ethics Service, 16/ES/0084) in line with the
Human Tissue (Scotland) Act (2006). Use of human tis-
sue for post-mortem studies was reviewed and approved
by the Edinburgh Brain Bank ethics committee and the
Academic and Clinical Central Office for Research and
Development medical research Ethics Committee.
Histology and neuropathological assessment
Brain tissue was taken post-mortem from standard-
ised Brodmann areas (BA), BA4 and BA9 and spinal
cord and fixed in 10% formalin for a minimum of
72 h. Tissue was dehydrated in an ascending alcohol
series (70–100%) followed by three successive 4 h
washes in xylene. Three successive 5 h paraffin wax
embedding stages were performed followed by cool-
ing and sectioning of the FFPE (formalin-fixed paraf-
fin embedded) tissue on a Leica microtome into 4 μm
thick sections that were collected on Superfrost micro-
scope slides. Sections were dried overnight at 40 ∘C
and immunostaining was performed, following epi-
tope retrieval in citric acid buffer (pH 6) in a pres-
sure cooker for 30min, using the Novolink Polymer
detection system with the Proteintech (Manchester, UK)
anti-phospho(409–410)-TDP-43 antibody at a 1 in 1000
dilution and Abcam (Cambridge, UK) anti-glutamate
receptor 1 antibody (ab32436) at a 1 in 50 dilution (both
incubated for 30min at room temperature). Counter-
staining was performed using DAB chromogen coun-
terstained with haematoxylin, according to standard
operating procedures. TDP-43 pathology was graded
semi-quantitatively by two independent pathologists,
using the following descriptive scoring system: (1) no
TDP-43 pathology; (2) mild TDP-43 pathology (up to 5
affected cells in at least one ×40 high power field (HPF)
out of three HPFs examined); (3) moderate TDP-43
pathology (5–15 affected cells in at least one ×40 HPF
out of three HPFs examined); severe TDP-43 pathology
(>15 cells affected in at least one ×40 HPF out of three
HPFs examined). Assessors were blinded to all demo-
graphic and clinical information. Motor neurons were
identified based on anatomical location within the spinal
cord and according to established neuropathological cri-
teria including size and morphology.
BaseScope analysis
FFPE tissue was sectioned at 4 μm thickness on to
Superfrost slides. BaseScope reagents (Advanced Cell
Diagnostics Inc., Newark, CA, USA) were used fol-
lowing the manufacturer’s guidelines according to the
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original protocol. In brief, following deparaffinisation,
tissue sections were incubated with hydrogen perox-
ide for 10 min at room temperature and target anti-
gen retrieval was performed by submerging slides in
BaseScope ×1 target retrieval reagent at 99 ∘C in a
Braun Multiquick FS 20 steamer for 15min. The tis-
sue was then permeabilised using BaseScope protease
III at 40 ∘C for 30min. Probe hybridisation was then
performed by incubating the slides with 4 drops of cus-
tom designed BaseScope probe, negative control probe
(dihydrodipicolinate reductase, DapB) or positive con-
trol (peptidyl-prolyl cis-trans isomerase B, PPIB) probe
for 2 h at 40 ∘C. Following successive probe amplifica-
tion steps, transcripts were detected using the BaseScope
RED detection kit and slides were counterstained using
haematoxylin and lithium carbonate. The slides were
then cleared in xylene and mounted with a 24× 50mm
coverslip using two drops of VectaMount mounting
medium. Sections were then imaged at ×20 objec-
tive magnification on a NanoZoomer slide scanner. An
unsharp mask in Photoshop was equally applied to all
BaseScope images to improve transcript signal visibil-
ity in panels, all quantification was performed using
direct visualisation under the microscope to facilitate
accurate transcript resolution. Motor neurons were iden-
tified according to established neuropathological crite-
ria including size and morphology. Number of spots/per
cell was counted for experimental GluA1–4 and PPIB
probes individually. Due to the sensitivity and speci-
ficity of BaseScope, one red dot corresponds to one
transcript, therefore transcript copy number values were
taken to be absolute. Counts were plotted as individual
transcripts per cell. GluATOTAL for each patient was cal-
culated by summing the subunits GluA1–4. The amount
of Ca2+-permeable AMPAR was estimated by taking
a ratio of (GluA1+GluA3+GluA4)/GluATOTAL. Pos-
itive (PPIB) and negative (DapB; a bacterial gene that is
not expressed in human tissue) control probes were also
quantified (number of spots/neuron) in the same way as
each of our experimental probes (GluA1–4). We did not
observe differences in PPIB expression between con-
trols and cases across all sampled regions (Figures 2A,
4A and 6A) and there was no expression of DapB in any
of the material examined (data not shown).
Induced pluripotent stem cell derived motor
neurons and GluA2 editing
Dermal fibroblasts from sALS patient and control indi-
viduals were obtained under full Ethical/Institutional
Review Board approval at the University of Edinburgh.
Fibroblasts were reprogrammed to iPSCs using epi-
somal vectors expressing OCT4, SOX2, C-MYC and
KLF4. iPSCs were maintained in Matrigel (BD Bio-
sciences, San Jose, CA, USA)-coated plastic dishes in
E8 medium (Life Technologies, Renfrew, UK) at 37 ∘C
and 5% CO2. Motor neurons were differentiated accord-
ing to a protocol detailed previously [15]. RNA editing
of the GluA2 subunit was performed exactly as detailed
previously [15].
Statistical analysis
The relative abundance of transcripts was quantified
by assessing the mean (±SD) number of red dots per
cell across 10 randomly identified cells in three ran-
domly generated fields of view (1mm2) for each case.
Cells within each field of view were randomly iden-
tified and to prevent bias the assessor was blinded to
all clinical and identifiable data and to the GluA1–4
subunit being assessed. Cases were compared using
one-way ANOVA with Bonferroni’s post hoc test to
account for multiple comparisons. Significance values;
*p < 0.05; **p < 0.01; ***p < 0.001. Fold-change com-
pared to GluA2 expression was performed by correcting
each case to its age and sex-matched control.
Results
This study has employed a highly sensitive in situ
hybridisation method (BaseScope) to examine the
expression of AMPAR subunit mRNA transcripts
(GluA1–4) at a single-cell level in post-mortem spinal
cord (anterior horn cells), motor cortex (BA4) and pre-
frontal cortex (BA9) tissue from sporadic, SOD1 I114T
and C9orf72RE ALS patients (three patients for each
ALS cohort). AMPAR expression in ALS post-mortem
tissue was compared to post-mortem tissue from three
age- and sex-matched controls with no clinical history
or pathological detection of neurodegenerative disease
(neuropathological data summarised in Table 1 and
cohort demographics in Table 2).
Control data
Our positive control slides localising PPIB transcripts
showed no observable difference in PPIB expression
between controls and cases across all sampled regions.
No staining was seen in our negative control slides.
By using both positive and negative controls, we have
confidence that our cases are directly comparable in
a robust and reproducible manner. Our PPIB data is
described and presented for each of the brain regions in
which AMPARs subunits were investigated.
AMPAR subunit expression is altered in sporadic,
C9orf72 repeat expansion and mutant SOD1 ALS
motor neurons
Previously we have shown transcriptional upregula-
tion of the Ca2+-permeable GluA1 AMPAR subunit
in C9orf72RE patient post-mortem anterior horn cells
(spinal motor neurons) compared to controls [15]. We
and others have shown that GluA1 mRNA expression in
adult spinal cord motor neurons is absent or negligible
[8,9,15,17,18]. To determine if this transcriptional dys-
regulation of AMPAR subunit is C9orf72RE mutation
specific, we extended our analysis to sALS and SOD1
I114T spinal motor neurons. Equivalent to C9orf72RE
patients, our data from sALS patients demonstrate an
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020; 250: 67–78
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Table 1. Summary of neuropathological assessment of cases
TDP-43 immunostaining p62 immunostaining
Case Spinal cord Prefrontal cortex Motor cortex
1 – sALS Anterior horn cells lost. Neuronal
inclusions highlighted by TDP-43,
p62 and Ubiquitin were seen. GFAP
highlighted reactive gliosis
Mild* abundance of neuronal
and glial TDP-43 inclusions
Mild* abundance of neuronal and
glial TDP-43 inclusions
There was no evidence of
non-TDP-43 related p62
staining
2 – sALS Anterior horn cells lost. The few
remaining anterior horn cells
contained inclusions which
immunoreacted for p62, TDP-43
and Ubiquitin. In addition, there
was extensive glial pathology
highlighted by TDP-43 and p62
Mild* abundance of neuronal
and glial TDP-43 inclusions
Mild* abundance of neuronal and
moderate* abundance of glial
TDP-43 inclusions
There was no evidence of
non-TDP-43 related p62
staining
3 – sALS Anterior horn cells lost. Cytoplasmic
inclusions were immunoreactive for
TDP-43 and were seen in residual
anterior horn cells throughout the
spinal cord
Mild* abundance of neuronal
and glial TDP-43 inclusions
Mild* abundance of neuronal and
glial TDP-43 inclusions
There was no evidence of
non-TDP-43 related p62
staining
1 – SOD1 Anterior horn cells lost. No TDP-43
inclusions were seen within the
neocortical ribbon, brain stem
nuclei or within residual anterior
horn cells
No evidence of neuronal or
glial TDP-43 inclusions
No evidence of neuronal or glial
TDP-43 inclusions
There was no evidence of
non-TDP-43 related p62
staining
2 – SOD1 Anterior horn cells lost. No TDP-43
inclusions were seen within the
neocortical ribbon, brain stem
nuclei or within residual anterior
horn cells
No evidence of neuronal or
glial TDP-43 inclusions
No evidence of neuronal or glial
TDP-43 inclusions
There was no evidence of
non-TDP-43 related p62
staining
3 – SOD1 Anterior horn cells lost. No TDP-43
inclusions were seen within the
neocortical ribbon, brain stem
nuclei or within residual anterior
horn cells
No evidence of neuronal or
glial TDP-43 inclusions
No evidence of neuronal or glial
TDP-43 inclusions
There was no evidence of
non-TDP-43 related p62
staining
1 – Control No pathology No pathology No pathology No pathology
2 – Control No pathology No pathology No pathology No pathology
3 – Control No pathology No pathology No pathology No pathology
1 – C9orf72 Anterior horn cells lost. TDP-43
inclusions were noted within
residual anterior horn cells
Mild* abundance of neuronal
and glial TDP-43 inclusions
Mild* abundance of neuronal and
glial TDP-43 inclusions
There was abundant p62
pathology within the amygdala,
hippocampus and cerebellum
2 – C9orf72 Anterior horn cells lost. TDP-43
inclusions were noted within
residual anterior horn cells
Mild* abundance of neuronal
and moderate* abundance
of glial TDP-43 inclusions
Mild* abundance of neuronal and
moderate* abundance of glial
TDP-43 inclusions
There was striking p62
immunoreactivity throughout
the neocortex and within the
hippocampus, particularly the
dentate gyrus. In addition, p62
expression was noted within
the cerebellar cortex
particularly within the granule
cell layer
3 – C9orf72 Anterior horn cells lost. TDP-43
inclusions were noted within
residual anterior horn cells
Mild* abundance of neuronal
and no evidence of glial
TDP-43 inclusions
Moderate* abundance of neuronal
and glial TDP-43 inclusions
There was abundant p62
pathology within the amygdala,
hippocampus and cerebellum
Abundance of pathological cortical TDP-43 inclusions (determined using an antibody against the pathologically phosphorylated form of TDP-43) are scored as follows:
*Mild (<5 affected cells in at least one ×20 field of view per section); *moderate (5–15 affected cells in at least one ×20 field of view per section); *severe (>15 cells
affected in at least one ×20 field of view per section). Spinal cord TDP-43 inclusion assessment is descriptive due to differences in abundance of anterior horn cells
(markedly reduced in number in ALS spinal cord).
increased GluA1 mRNA abundance in the anterior horn
cells of the spinal cord with respect to controls which
displayed no measurable level of GluA1 transcripts,
whilst displaying equivalent expression of the posi-
tive control transcript, PPIB (Figures 1A and 2A,B).
For ease of comparison, we have presented the raw
quantified AMPAR subunit transcript data previously
published for C9orf72RE patient post-mortem anterior
horn cells (and respective controls; [15], Figure 2B).
However, SOD1 I114T patient samples did not express
GluA1 transcripts in anterior horn motor neurons
(Figures 1 and 2B. These data were further confirmed
by immunohistochemical (IHC) staining for the GluA1
subunit (protein) in post-mortem spinal cord tissue and
finding increased staining for GluA1 in the anterior
horn cells (spinal motor neurons) of C9orf72RE and
sALS cases, with no staining for GluA1 in control
individuals and SOD1 cases (Figure 1B). Given that
TDP-43 pathology is a common pathological signature
observed in C9orf72RE and sALS and absent in mutant
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020; 250: 67–78
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Table 2. Patient and control cohort characteristics
Patient Sex Age Disease duration
1 – sALS M 54 66
2 – sALS M 70 16
3 – sALS F 68 24
1 – C9orf72 F 62 97
2 – C9orf72 F 63 109
3 – C9orf72 F 63 33
1 – SOD1 M 64 67
2 – SOD1 F 68 127
3 – SOD1 F 56 98
1 – Control M 58 N/A
2 – Control M 65 N/A
3 – Control F 68 N/A
Age indicates age at death; disease duration indicates months from
symptom-onset to death.
SOD1 patient post-mortem brain tissues [16,19], these
data support an association between TDP-43 pathology
and the transcriptional dysregulation of GluA1 in spinal
cord motor neurons. Indeed, prominent pathological
TDP-43 aggregation was observed in the anterior horn
cells of sALS and C9orf72RE patients but was not
present in SOD1 I114T patient samples (Table 1).
The GluA2 subunit typically controls and confers
Ca2+-impermeability onto the AMPAR ion channel [7]
and its reduced expression (which would result in cal-
cium permeability) has been previously highlighted as
a factor that may underpin increased vulnerability of
ALS motor neurons to glutamate excitotoxicity [9,13,
20]. However, the data in our study demonstrate that, in
direct contrast toC9orf72RE, sALS patients and controls,
GluA2 mRNA expression was not detectable in SOD1
I114T anterior horn cells indicating exclusive expres-
sion of Ca2+-permeable AMPARs. We did not exam-
ine protein expression of the GluA2 (and GluA3 and
GluA4) subunits given the inability of antibodies to dis-
criminate between these AMPAR subunits. To assess
the impact of alterations in AMPAR subunit expression
upon the potential functional Ca2+-permeable versus
Ca2+-impermeable AMPAR identity in each of the
ALS patients and control individuals, we initially cal-
culated the ratio of GluA2 subunit mRNA expres-
sion with respect to total AMPAR subunit expression
(GluA2/GluATOTAL) for each ALS group, where 0 and
1 reflect purely Ca2+-permeable and Ca2+-impermeable
AMPARs populations respectively (Figure 2C). Surpris-
ingly, despite an abnormal increase in GluA1 tran-
script level, we found that sALS motor neurons exhib-
ited a GluA2/GluATOTAL ratio that was comparable to
that of control individuals. However, C9orf72RE patients
had significantly lower GluA2/GluATOTAL, which was
therefore consistent with an increased Ca2+-permeable
AMPAR population.
To understand how expression of GluA1, GluA3
and GluA4 subunits individually contribute to the pre-
dicted total Ca2+-permeable versus Ca2+-impermeable
AMPAR identity we normalised each subunit data
relative to GluA2 subunits (Figure 2D). This analysis
confirmed that GluA1 expression was substantially ele-
vated in anterior horn cells of both sALS and C9orf72RE
with respect to control individuals. However, considered
together with the GluA2/GluATOTAL data displayed in
Figure 2C, the impact of increased GluA1 expression in
sALS patients appears to be compensated by a decrease
in the relative expression of GluA4 transcripts, which
was significantly reduced with respect to control cases.
For C9orf72RE patients, the relative expression data
for GluA3 and GluA4 subunits were not significantly
changed with respect to control patient data. The large
standard deviation for the relative expression data of
GluA3 and GluA4 subunits is due to a high degree of
reciprocal variability between patients (Table 3). The
Figure 1. Characterisation of AMPAR subunit mRNA expression
in human post-mortem anterior horn cells. (A) Representative
images of BaseScope in situ hybridisation demonstrating quantifi-
able expression of GluA1, GluA2, GluA3 and GluA4 AMPAR subunit
mRNA in anterior horn cells of control, C9orf72RE , sALS and SOD1
I114T ALS cases. The red dots (arrows) represent individual detected
mRNA molecules. Red arrows highlight cells with mRNA expres-
sion and white arrows indicate low/no expression. Note the lack of
GluA1 transcripts within control patient spinal cord cells and the
presence of GluA1 within sALS and C9orf72RE patient cells. Note
the lack of GluA2 (and GluA1) in SOD1 I114T patient cells. Scale
bar, 20 μm. (B) Representative images of IHC staining for the GluA1
subunit within the anterior horn of the spinal cord of control indi-
viduals as well as sALS, C9orf72 and SOD1 cases. White arrows
indicate anterior horn cells (spinal motor neurons) with no staining
and red arrows indicate anterior horn cells (spinal motor neurons)
with IHC staining for GluA1. Indicating increased levels of GluA1
subunit (protein) detected by IHC.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020; 250: 67–78
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Figure 2. Quantification of cellular AMPAR subunit mRNA transcript expression within anterior horn cells. (A) Mean (±SD) number of
positive-control PPIB mRNA transcripts per cell (dots per cell= number of mRNA transcripts per cell) within the anterior horn cells of
sALS, C9orf72RE , SOD1 I114T and control individuals. (B) Mean (±SD) number of GluA1, GluA2, GluA3 and GluA4 AMPAR subunit mRNA
transcripts per cell within anterior horn cells of three control, C9orf72RE , sALS and SOD1 I114T ALS cases. Note the detection of GluA1
transcripts in sALS and C9orf72RE patients contrasting against the absence of GluA1 transcripts in control patients. Note the absence of
GluA2 (and GluA1) transcripts in SOD1 I114T patients. C9orf72RE repeat expansion patient data has been previously presented in [14].
PPIB and AMPAR data from each patient was a mean determined from a total of 30 cells from three randomly generated fields of view (10
cells/field of view). C9orf72RE patient data has been previously presented in [15]. (C) Mean (±SD) relative expression of GluA2 subunit mRNA
expressed as a percentage with respect to total AMPAR subunit transcripts (GluA2/GluATOTAL). (D) Mean (±SD) normalised fold-expression
of Ca2+-permeable GluA1, GluA3 and GluA4 AMPAR subunit mRNA with respect to (w.r.t.) GluA2 transcripts. (E) Representative gel picture
showing efficient GluA2 Q→R RNA editing in week 3 cultures in sALS and control individual lines. RFLP analysis is on the right, where
efficient GluA2 RNA editing results in RFLP amplicons of 116 and 66 bp. A band at 81 bp would be observed with inefficient GluA2 subunit
editing. The PCR product for GluA2 is shown on the left indicating GluA2 expression. Statistical analysis performed with one-way ANOVA
with Bonferroni’s post hoc correction. Statistical significance highlighted is with respect to control individuals. We calculated GluATOTAL for
each patient by summing the subunits GluA1–4.
abnormal increase in GluA1 in C9orf72RE patient motor
neurons therefore appears to be uncompensated leading
to an increase in Ca2+-permeable AMPARs.
Sporadic ALS post-mortem spinal cord motor neu-
rons also exhibit inefficient RNA editing of the GluA2
subunit [10]. This appears to be an sALS-specific fea-
ture since mutant SOD1 post-mortem motor neurons
[20] and C9orf72RE patient-derived motor neurons
[15] do not exhibit inefficient GluA2 editing. Because
BaseScope probe design is not yet conducive for
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020; 250: 67–78
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Table 3. Reciprocal expression of GluA3 and GluA4 in C9orf72RE
spinal cord motor neurons
GluA3 GluA4
Case Mean SD Mean SD
1 – C9orf72 4.6 0.84 19.9 5.09
2 – C9orf72 2.8 0.42 21 4.24
3 – C9orf72 12.7 2.21 5 0.82
1 – Control 2.8 1.32 3.7 2.00
2 – Control 2.6 1.78 3.1 1.20
3 – Control 2.6 1.51 4 1.83
1 – SOD1 2.5 1.58 3.5 1.08
2 – SOD1 2.4 1.43 3.6 1.35
3 – SOD1 2.8 2.25 3.8 1.03
1 – sALS 4.7 0.48 22.6 4.20
2 – sALS 5.1 0.88 21.7 4.16
3 – sALS 2.3 0.67 21.8 6.65
Mean and SD of the number of GluA3 and GluA4 mRNA transcripts in each case,
demonstrating reciprocal expression profiles. Light shading – higher expression;
Dark shading – lower expression; No shading – no difference in expression.
comparison of unedited versus edited GluA2 lev-
els (essentially a single base pair substitution) we
examined the efficiency of GluA2 editing in enriched
cultures of motor neurons differentiated in vitro from
induced pluripotent stem cells obtained from a sALS
patient, as described previously [15]. We employed
restriction fragment length polymorphism (RFLP)
analysis using the restriction enzyme Bbv1 and this
indicated that GluA2 editing is highly efficient in sALS
patient-derived motor neurons (Figure 2E).
Ca2+-permeable AMPAR subunit expression is
elevated in the motor cortex of sporadic ALS
patients
The principle feature of ALS is degeneration of both
lower and upper motor neurons. We therefore exam-
ined whether expression of AMPAR subunit transcripts
in cortical motor neurons (upper motor neurons, BA4)
are altered in sALS, C9orf72RE and SOD1 I14T patients
(Figure 3A). Motor cortex samples displayed equivalent
staining for PPIB (Figure 4A) and subsequent quantifi-
cation of AMPAR subunit mRNA transcripts revealed
the variable expression of all transcripts in all ALS cases
examined (Figure 4B). For the first time, we showed
that C9orf72RE patients expressed comparable levels of
AMPAR subunit expression with respect to control indi-
viduals in cortical motor neurons with the exception of
a modest increase in levels of the GluA4 subunit tran-
script. Interestingly, we observed a profound reduction
of GluA2 subunit expression in sALS cases and mod-
est reductions in GluA3 and GluA4 subunit expression.
In contrast, SOD1 I114T patients displayed reduced
expression of each of the AMPAR subunits when com-
pared to control individuals (Figure 4B).
To estimate the levels of Ca2+-permeable AMPARs in
cortical motor neurons, we assessed GluA2/GluATOTAL,
as discussed for anterior horn cells. Importantly,
GluA2/GluATOTAL was found to be substantially
reduced in sALS, but not C9orf72RE or SOD1 I114T,
patients compared to control motor cortex (Figure 4C).
Figure 3. Characterisation of AMPAR subunit mRNA expression
in human post-mortem motor cortex tissue. Data as described
in Figure 1, but for the motor cortex (BA4). Note the increased
detection of Ca2+-permeable GluA1, GluA3 and GluA4 AMPAR
subunit mRNA transcripts relative to GluA2 transcripts in sALS
patients. (B). Representative images of IHC staining for GluA1
subunit within the motor cortex of control individuals as well
as sALS, C9orf72 and SOD1 cases. Red arrows indicate cortical
motor neurons with positive IHC staining for GluA1. Indicating no
discernible difference in levels of GluA1 subunit (protein) detected
by IHC.
Therefore, despite sALS and C9orf72RE patients both
exhibiting TDP-43 pathology (Table 1), sALS neurons
of the motor cortex only exhibit a transcript profile
consistent with an increased Ca2+-permeable AMPAR
population.
To understand this change in AMPAR dysregulation
in sALS patients with respect to control individuals, we
then normalised each AMPAR subunit data relative to
GluA2 (Figure 4D). Notably, we observed a 2- to 3-fold
significant increase in the levels for all Ca2+-permeable
subunits (GluA1,GluA3 andGluA4) with respect to con-
trols. This is a reflection of normalisation to GluA2,
which is substantially reduced with respect to control
individuals. Inspection of the raw transcript data in
Figure 4B indicates a substantial reduction ofGluA2, but
not GluA1, GluA3 or GluA4 transcripts with respect to
control data. These data indicate that the motor cortex
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Figure 4. Quantification of cellular AMPAR subunit mRNA transcript expression within motor cortex tissue. (A) Mean (±SD) number of
positive-control PPIB and (B), mean (±SD) AMPAR subunit mRNA transcripts per cell as described in Figure 1, but for the motor cortex.
(C) Mean (±SD) relative expression of GluA2 subunit mRNA expressed as a percentage with respect to total AMPAR subunit transcripts
(GluA2/GluATOTAL). (D) The mean (±SD) normalised fold-expression of Ca2+-permeable GluA1, GluA3 and GluA4 AMPAR subunit mRNA
with respect to (w.r.t.) GluA2 transcripts. Note the increased detection of Ca2+-permeable GluA1, GluA3 and GluA4 AMPAR subunit mRNA
transcripts relative to GluA2 transcripts in sALS patients. Statistical analysis performed with one-way ANOVA with Bonferroni’s post hoc
correction. Statistical significance highlighted is with respect to control individuals.
of sALS patients exhibit a transcriptional downregula-
tion of the GluA2 subunit, which is consistent with a
Ca2+-permeable AMPAR phenotype.
Relative GluA1 AMPAR subunit expression is
elevated in the prefrontal cortex of sporadic ALS
patients
To determine whether AMPAR subunit dysregulation
is associated with upper and lower motor neurons or,
non-motor neurons in other brain regions also affected
by TDP-43 pathology in ALS patients we examined
AMPAR subunit expression in the post-mortem pre-
frontal cortex (BA9) of sALS, C9orf72RE and SOD1
I114T patients (Figure 5A). Cellular quantification of
positive control PPIB (Figure 6A) and AMPAR subunit
transcripts was performed as for sALS and SOD1 I114T
patients (Figure 6B). Previously published quantified
C9orf72RE AMPAR subunit data for the prefrontal
cortex [15] is presented for comparison (Figure 6B).
All AMPAR subunit transcripts were detected in each
of the cases and control individuals. AMPAR sub-
units were not extensively altered in prefrontal cortex
neurons in C9orf72RE and SOD1 I114T cases. How-
ever, in sALS cases, GluA2 and GluA3 transcripts
were reduced substantially and there was a significant
upregulation of GluA1 mRNA (Figure 6B). These data
were further confirmed by IHC staining for the GluA1
subunit (protein) in post-mortem prefrontal cortex,
demonstrating a possible increase in staining for GluA1
in the neurons of sALS cases compared to controls
(Figure 5B).
Strikingly, the GluA2/GluATOTAL ratio in the pre-
frontal cortex of sALS patients was lower than in
controls, therefore suggesting a substantially larger
Ca2+-permeable AMPAR population (Figure 6C).
GluA2/GluATOTAL prefrontal cortex data generated
for C9orf72RE and SOD1 I114T patients revealed no
significant difference in the GluA2/GluATOTAL ratio
(Figure 6C). Of interest, we additionally note that
for the prefrontal cortex of control individuals that
GluA2/GluATOTAL ratios are significantly higher than
that of the motor cortex (p < 0.01, unpaired t-test) and
anterior horn cells (p < 0.001, unpaired t-test), indicat-
ing the different transcriptional regulation of AMPAR
subunits between different brain regions.
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Figure 5. Characterisation of AMPAR subunit mRNA expression in
human post-mortem prefrontal cortex tissue. (A) Data as described
in Figure 1, but for the prefrontal cortex. Note the increased detec-
tion of Ca2+-permeable GluA1 AMPAR subunit mRNA transcripts
relative to GluA2 transcripts in sALS patients. (B) Representative
images of IHC staining for GluA1 subunit within the prefrontal cor-
tex of control individuals as well as sALS, C9orf72 and SOD1 cases.
Red arrows indicate cortical neurons with positive IHC staining for
GluA1. Images indicate a possible mild increase in GluA1 staining
in the sALS and decrease in SOD1 cases consistent with the mRNA
transcript abundance in (A), however, there was no definite dis-
cernible difference in levels of GluA1 subunit detected.
We then examined how the shift in GluA2/GluATOTAL
ratio in sALS prefrontal cortex with respect to control
was underpinned by regulation of individual AMPAR
subunits by normalisation of each subunit data to GluA2
for each patient (Figure 6D). GluA1 transcript expres-
sion was found robustly enhanced in the post-mortem
motor cortex of sALS patient versus control cases,
whilst the relative expression of GluA3 and GluA4 was
not significantly different from that in control individu-
als. The dysregulation of GluA1 subunit expression in
the prefrontal cortex of sALS patients is therefore likely
to underpin the observed reduction in GluA2/GluATOTAL
ratio. Conversely, C9orf72RE and SOD1 I114T patients
did not exhibit any notable changes in the relative
expression of the Ca2+-permeable subunits GluA1,
GluA3 and GluA4 in the prefrontal cortex. The data
therefore demonstrate that the observed dysregulation
of AMPAR subunit expression in the prefrontal cortex
is specific to sALS patients. Furthermore, the fact that
the prefrontal and motor cortex of sALS and C9orf72RE
patients shows overlapping TDP-43 pathology (Table 1)
suggests that TDP-43 cannot be the sole pathogenic sub-
strate that generates altered Ca2+-permeable AMPAR
subunit expression in the cortical regions of sALS
patients.
Discussion
This study has provided the first comparative study
of AMPAR subunit expression across post-mortem
brain regions (spinal cord – anterior horn, motor cor-
tex – BA4 and prefrontal cortex – BA9) of the most
prevalent genetic ALS patient cohorts; sporadic ALS,
SOD1mutation and C9orf72RE. To do this we employed
a high resolution in situ hybridisation technique,
BaseScope, which permitted a quantitative assessment
of AMPAR subunit expression at the single-transcript
and single-cell level previously not detailed in control
individuals or ALS patients. Whilst it is not possible
in post-mortem tissue, using laser capture dissection or
in situ hybridisation, to capture a neuron in its entirety,
we have sampled multiple cells in multiple regions to
try to limit sampling bias, as other studies have done
[9]. Using these methods, our data indicate extensive
AMPAR subunit dysregulation in all brain regions
examined from sALS patients. However, AMPAR dys-
regulation was observed to be restricted to spinal motor
neurons for SOD1 I114T and C9orf72RE patients.
AMPAR subunit dysregulation in spinal motor neu-
rons has been described in several ALS models [20] and
in human ALS patients [9], where mechanistic disease
hypotheses have centred on an increased vulnerability
to excitotoxicity due to an increased Ca2+-permeable
AMPAR population in these cells. Previously [15], we
showed that C9orf72RE spinal motor neurons exhibited
an increased functional Ca2+-permeable AMPAR pop-
ulation underpinned by an increase in the abnormal
expression of the GluA1 subunit and, in this study, is
reflected as a reduction in the GluA2/GluATOTAL expres-
sion ratio. Noting the expression ofGluA1 in adult spinal
motor neurons is consistently reported to be absent
or negligible [15], we found that sALS patient spinal
motor neurons exhibit equivalent substantial dysregu-
lation of GluA1 transcripts and protein. This indicates
that sALS and C9orf72RE spinal motor neurons, which
both exhibit TDP-43 pathology, may share pathologi-
cal mechanisms. Indeed, the GluA2/GluATOTAL expres-
sion ratio for sALS spinal motor neurons was, sur-
prisingly, not different to that of control individuals
and the observed reduced expression of Ca2+-permeable
GluA4 subunit may instead reflect compensatory mech-
anisms for the increased GluA1 expression in sALS
patients. These specific data suggest to us that sALS
patients do not exhibit differences in the relative level
of the Ca2+-permeable AMPAR population in spinal
motor neurons. However, a functional Ca2+-permeable
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Figure 6. Quantification of cellular AMPAR subunit mRNA transcript expression within prefrontal cortex tissue. (A) Mean (±SD) number of
positive-control PPIB and (B), mean (±SD) AMPAR subunit mRNA transcripts per cell as described in Figure 1, but for the prefrontal cortex.
C9orf72RE repeat expansion patient data has been presented previously in [15]. (C) Mean (±SD) relative expression of GluA2 subunit
mRNA expressed as a percentage with respect to total AMPAR subunit transcripts (GluA2/GluATOTAL). (D) Graph showing the mean (±SD)
normalised fold-expression of Ca2+-permeable GluA1, GluA3 and GluA4 AMPAR subunit mRNA with respect to (w.r.t.) GluA2 transcripts.
Note the increased detection of Ca2+-permeable GluA1 AMPAR subunit mRNA transcripts relative to GluA2 transcripts in sALS patients.
Statistical analysis performed with one-way ANOVAwith Bonferroni’s post hoc correction. Statistical significance highlighted is with respect
to control individuals.
AMPAR population still cannot be ruled out given that
AMPAR assembly, trafficking and localisation is highly
subunit dependent [21] and that the underlying profile of
AMPAR subunit expression is different in sALS patients
to that of control individuals.
GluA1 was not expressed by SOD1 I114T patients,
which do not exhibit TDP-43 pathology, confirm-
ing GluA1 dysregulation is associated with common
TDP-43 pathology. However, we observed that only
Ca2+-permeable AMPARs could be expressed by SOD1
I114T spinal motor neurons since GluA2 was found
not to also be expressed. These data are the first to be
presented in the context of human ALS patients with
SOD1 mutations, though are in broad agreement with
previous studies of mutant Sod1 rodent models of ALS
that implicate a reduction in GluA2 expression in spinal
motor neurons [11,13,23–27]. Despite mechanistic
divergence at the AMPAR subunit transcriptional level,
it appears that SOD1 mutant and C9orf72RE patient
spinal motor neurons show a functional convergence
through an increase in the relative Ca2+-permeable
AMPAR population.
Inefficient (glutamine to arginine) RNA editing
of the GluA2 subunit also generates an increase in
Ca2+-permeable AMPARs and has been evidenced
in sALS post-mortem spinal motor neurons [10], but
not SOD1 mutation post-mortem motor neurons [21],
C9orf72RE motor neurons [15] and whole spinal cord
lysates from C9orf72RE patients [27]. We examined
GluA2 editing in sALS patient-derived motor neurons
and found the editing of GluA2 to be highly efficient.
ALS is also typified by the degeneration of upper
motor neurons and several other brain regions are
also affected by TDP-43 deposition. We therefore
performed a comparative quantitative assessment of
AMPAR subunit expression in the ALS motor cortex
(BA4) and pre-frontal cortex (BA9). Our data indi-
cated that SOD1 I114T and C9orf72RE patients did
not exhibit any change in GluA2/GluATOTAL expression
or subunit profiles with respect to control individu-
als in the cortical areas investigated and indicate that
AMPAR dysregulation is restricted to spinal motor
neurons. Despite sharing equivalent TDP-43 pathology
with C9orf72RE patients, dysregulation of AMPAR
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subunit expression in the motor and prefrontal cor-
tex of sALS patients is, however, prominent. The
GluA2/GluATOTAL expression ratio in the pre-frontal
cortex and motor cortex in sALS is lower due to an
increase in GluA1 expression and a reduction in GluA2
expression, respectively. TDP-43 pathology alone
therefore cannot account for the observed differential
spatial AMPAR dysregulation. These scenarios lead
to an increase in Ca2+-permeable AMPARs in sALS
motor and pre-frontal cortex and suggest that they may
contribute to excitotoxic-mediated cell death. In this
regard, we highlight that GluA2/GluATOTAL expression
ratios are estimations and not direct measurements of
the functional Ca2+-permeable AMPAR composition.
Our data indicate that neuronal AMPAR subunit
expression is heterogeneously regulated between ALS
cases with different genetic backgrounds and between
different brain regions within each case type. Fur-
thermore, given that sALS patients exhibited altered
AMPAR subunit regulation in all regions examined and
C9orf72RE patients only in anterior horn motor neu-
rons, it appears that classical TDP-43 pathology can
only be associated with aspects of anterior horn motor
neuron, but not cortical, AMPAR subunit dysregulation.
Nonetheless, with the potential exception of sALS ante-
rior hornmotor neurons, all observed perturbedAMPAR
subunit expression is consistent with a convergence on
an increased relative Ca2+-permeable AMPAR popula-
tion, which is thought to underpin an increased vulnera-
bility to glutamate-mediated neurotoxicity.
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